CANC — Tema Oncology ETF

Is CANC overbought or oversold? Here is the current MarketMoodz read.

ETF

Overbought As of August 19, 2026

Tema Oncology ETF (CANC) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The ETF name last closed at $43.82. The rating moved from Neutral to Overbought on August 6, 2026.

See all overbought ETF stocks →

AI analysis

Tema Oncology ETF provides targeted exposure to oncology and cancer-therapy developers, offering access to secular growth driven by R&D advances, aging demographics, and potential M&A. Thematic diversification within the oncology space reduces single-name risk relative to owning individual biotech equities, but the fund remains event-driven and prone to clinical/regulatory swings. Near-term market tone (mild risk-on and rotation into growth) is supportive for short-term inflows, though options-market complacency and macro uncertainty create downside vulnerability. Liquidity, tracking error, and concentration in high-volatility biotech names are the primary operational and market risks. Over the next month, performance will likely hinge on sector-specific catalysts (trial readouts, approvals, deal activity) and the broader risk sentiment backdrop.

Key factors

  • Focused thematic exposure to oncology and cancer therapeutics benefiting from secular growth in oncology R&D and aging populations
  • High potential upside from successful clinical readouts, regulatory approvals, and industry M&A activity that disproportionately benefit oncology-focused holdings
  • ETF structure provides diversified access to multiple biotech and pharma names within oncology, reducing single-stock idiosyncratic risk versus holding individual developers
  • Current market tone shows mild risk-on and rotation into growth sectors, which can support short-term inflows into thematic biotech/oncology ETFs
  • Relative lack of recent negative headline geopolitics tied to oncology sector—flows are more driven by scientific catalysts than macro headlines
  • Options-market complacency and low IV rank in broad indices can create asymmetric upside if biotech-specific catalysts re-price risk premia

Risks

  • High concentration and event-driven volatility from clinical trial failures or negative regulatory decisions for major holdings
  • Liquidity and tracking risk typical of thematic ETFs, including wider bid-ask spreads and potential intraday price divergence from NAV during stress
  • Macro volatility: a sudden move to risk-off driven by rate shocks, geopolitical events, or equity-wide volatility spikes could trigger sharp outflows
  • Sector correlation with broader biotech/pharma: negative sector-wide news (e.g., safety concerns, pricing policy) can rapidly depress ETF value
  • Limited public financial disclosure specific to the ETF’s active holdings and rebalancing cadence increases uncertainty about near-term positioning
  • Options-market mispricing (cheap protection) raises the chance of sudden downside during headline shocks

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CANC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.